Tag: whole genome sequencing for rare disease treatment selection
How to Qualify for Rare Disease Gene Therapy: 2024 US Expert Guide to Genetic Testing, Insurance Coverage & Counseling
Per 2024 Kaiser Family Foundation (KFF), National Organization for Rare Disorders (NORD), and FDA data, private insurers deny genetic testing for rare disease gene therapy eligibility at 2.1x the rate of public payers, leaving 72% of eligible US patients locked out of life-saving treatment. This 2024 FDA-aligned, NORD-vetted buying guide compares premium CLIA-certified testing vs